SCHEMBL6985141

SCHEMBL6985141

COC(=O)C1CCCN1C(=O)c1ccc2c(c1)CCCN2C(=O)CCc1ccc(C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 3/20 0.47
TP53 P04637 1/20 0.43
PDK2 Q15119 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
DPP4 P27487 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LOX P28300 1/20 0.39
KDM1A O60341 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985246 0.83 TP53 (0.51) TP53PDK2NPC1RAB9AHDAC1
SCHEMBL6985146 0.83 AVPR2 (0.40) AVPR2NPC1RAB9ADPP4LOX
SCHEMBL7410530 0.81 TP53 (0.45) TP53PDK2HDAC1HDAC8HDAC6
Hydrochloric Acid SCHEMBL6984559 0.80 ALDH1A1 (0.47) AVPR2ALDH1A1SMN1; SMN2
SCHEMBL6981826 0.80 PDK1 (0.52) AVPR2TP53PDK2HDAC1HDAC8
SCHEMBL6985351 0.79 ALDH1A1 (0.54) TP53PDK2HDAC1HDAC8HDAC6
Hydrochloric Acid SCHEMBL6979845 0.78 ALDH1A1 (0.44) AVPR2ALDH1A1SMN1; SMN2
SCHEMBL6987041 0.77 CDK1 (0.45) TP53PDK2HDAC1HDAC8HDAC6
SCHEMBL6986538 0.76 TP53 (0.49) AVPR2TP53PDK2NPC1RAB9A
SCHEMBL6979174 0.76 TP53 (0.50) TP53DPP4HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed